Glioblastoma multiform, (GBM) is the most aggressive form of the primary brain tumors known as gliomas. The tumors do not spread throughout the body like other forms of cancer, but cause symptoms by invading the brain.

A new drug called AZD2171 (Recentin), is an angiogenesis inhibitor that blocks tumor blood supply and shows promise in treating deadly glioblastoma brain cancers. Recentin suppresses the growth of blood vessels that feed the tumors.

The preliminary findings of the Phase II study show that researchers found that Recentin could significantly reduce the size of glioblastoma tumors and can help reduce brain swelling.

"Patients with recurrent glioblastomas desperately need new, effective treatment alternatives," said study author Dr. Tracy Batchelor, chief of neuro-oncology.

Mushrooms can help prevent breast cancer, says a study published in Cancer Research, by suppressing estrogen production in the body. Controlling estrogen levels in women can help limit or prevent cancer growth.

Researchers confirmed the presence of anti-aromatase chemicals in white button mushrooms. The chemical found called conjugated linoleic acid has previously been found to have anti-cancer properties. In mice, these compounds stopped the growth of breast cancer cells.The mice that were fed mushroom extract had a 58 percent reduction in breast tumor growth.

They tested other mushrooms and found that although white button mushrooms had the strongest effect, shiitake, portobello, crimini, and baby button mushrooms also had significant anti-aromatase effects.

Previous posts on this topic:

Medicinal mushrooms: cancer treatment cancer prevention

Recipe for Healthy Living: Mushroom Garlic Soup

Recent preliminary results from a Phase II clinical trial showed patients with recurrent glioblastoma multiforme, a form of primary brain cancer, experienced a significant tumor response rate with minimal side effects when treated with enzastaurin, an oral, targeted agent under development at Eli Lilly and Company.

On Thursday Eli Lilly & Co announced that it has stopped the Phase III trial of this experimental brain cancer drug. They determined that the treatment would not be any more effective than current chemotherapy treatments. The company said that it will still be evaluating enzastaurin as a potential treatment for non-Hodgkin's lymphoma. They will also be doing some trials that test the drug on other cancers, such as breast, colon, lung, ovarian and prostate.

Enzastaurin belongs to the families of drugs called protein kinase inhibitors and angiogenesis inhibitors.

Torisel is a protein inhibitor to be filed for approval for the treatment of cancer. It's an investigational drug that inhibits mTOR, a protein that regulates cell proliferation, cell growth and cell survival.

Wyeth Pharmaceuticals is seeking an indication for Torisel for the treatment of advanced renal cell carcinoma. If approved this drug would be a significant improvement compared with existing therapies. Results from a Phase III clinical trial showed that out of 626 patients, overall survival was increased by 49 percent.

Torisel will be available prior to FDA approval through an Expanded Access Program (EAP). For more information you can call 1-800-234-8243 or go to the website www.clinicaltrials.gov.